Honors, Awards and Publications
Susan Kruse Sullivan, RN, and Jill
Siegfried, MS,
collaborated with other Cancer Center staff members
on the following article:
Sullivan, SK, Schuricht, AL, Siegfried, JD, Fede,
JM, Victoria, T. Duodenal
somatostatinoma and gastrointestinal stromal
tumor associated with neurofibromatosis. Community Oncology, 2006;
3: 266-270.
Mary Pat Lynch, CRNP, MSN,
AOCN,
Cancer Center Administrator, published the
following article:
Lynch, MP, Diagnostic Reasoning:
Dyspnea. Clinical
Journal of Oncology Nursing, 10 (3); 323-326.
David
Mintzer, MD, Chief of Oncology/Hematology,
published the following articles:
- Janne PA, Wozniak
AJ, Belani CP, Keohan M-L, Ross HJ, Polikof
JA, Mintzer DM, Taylor L, Ashland J,
Ye Z, Monberg MJ, Obasaju CK. Open-label
study of pemetrexed alone or in combination
with cisplatin for the treatment of patients
with peritoneal mesothelioma: outcomes of an
expanded access program.
Clinical Lung Cancer 7: 40-6, 2005.
- Davis A,
Klitus M, Mintzer DM. Chemotherapy-induced
amenorrhea from adjuvant breast cancer treatment:
the effect of the addition of taxanes.
Clinical Breast Cancer 6:421-4; 2005
- Maguire
WF, Mintzer DM, Stopyra GA, Stern J. Strongyloidiasis
diagnosed by endoscopic biopsy in a
patient with multiple myeloma. Community
Oncology 3: 144-6; 2006.
- Treat J, Bonomi P,
McCleod M, Christiansen NP, Mintzer DM, Monberg
M, Ye Z, Chen R, Obasaju C.
Administration of pemetrexed immediately
following gemcitabine as front-line therapy
in advanced non-small
cell lung cancer: A phase II trial. Lung Cancer.
2006; 53(1):77-83.
- Mintzer DM. The heart
and mind of cancer care. Book review: A physicians'
guide to pain and symptom
management in cancer patients (2nd edition).
Community Oncology 3, 29; 2006.
- Mintzer D, Schwartzberg
LS, Cobb P, Henry D, Fortner BV. Phase II
trial of nanoparticle albumin +
capecitabine in first line therapy of metastatic
breast cancer. Proc ASCO 18S: 10731; 2006.
Anthony Meadows, PhD, MT-BC, music therapist,
was recently named assistant
professor of music, Department of Music Therapy,
Immaculata University.
He is also a faculty member in the new Music
and Imagery Institute at Anna
Maria College in Boston. He is editing Qualitative
Inquiries in Music Therapy,
Volume 3, to be published in September.
David
Henry, MD, Director of Penn HIV
Oncology Program,
published the following articles:
- Henry, D.H.
Final results of a randomized study comparing
two dosing regimens of epoetin alfa in
patients with chemotherapy-induced anemia:
80,000 U every two weeks vs. 40,000 U weekly.
Poster presented at 2006 American Society of
Clinical Oncology (ASCO) Annual meeting.
- Glaspy,
J., Henry, D., Canon, J., Lam, H., Lillie,
T. Darbepoetin alfa administered at varying
intervals compared with weekly epoetin alfa
for treating chemotherapy induced anemia: a
pooled
analysis of 20 clinical trials. Proc ASCO
18S: 18508: 2006.
- Nagle, D., Henry, DH, Iagaru,
A., Mastoris, L., Chmielewski, J., Rosenstock,
J. The utility of PET
scanning in the management of squamous cell
carcinoma of the anus. Proc ASCO 18S: 4152;
2006.
- Henry, DH, Shasha, D. Hematopoietic response
to extended dosing of epoetin alfa 60,000 U
every
2 weeks in anemic cancer patients not receiving
therapy: Final results. Blood (ASH Annual
Meeting Abstracts) 2005; 106; Abstract 3764.
- Henry,
DH, Xie, J., Woodman, RC. Randomized, Open-Label
study of Epoetin alfa 40,000 U
once weekly vs. 80,000 U every two weeks in
anemic patients with cancer receiving chemotherapy.
Blood (ASH Annual Meeting Abstracts) 2005;
106; Abstract 3772.
- Fesnak, A., Mastoris, J.,
Ley, S., Henry, DH. Routine blood draw during
chemotherapy does not
cause significant iron deficiency. Blood
(ASH Annual Meeting Abstracts) 2005; 106; Abstract
3720.
- Grote, T., Yeilding, AL, Castillo, R.,
Butler, D., Fishkin, E. Henry, D., DeLeo, M.,
Fink, K.,
Sullivan, DJ. Efficacy and safety analysis
of epoetin alfa in patients with small-cell
lung cancer: a
randomized, double-blind placebo-controlled
trial. J. Clin. Oncology. 2005 Dec., 20:
23(36) 9377-86.
- Glaspy, J., Henry, D., Patel,
R. et al. Effects of chemotherapy on endogenous
erythropoietin levels
and the pharmacokinetics and erythropoietic
response of darbepoetin alfa: a randomized
clinical
trial of synchronous versus asynchronous dosing
of darbepoetin alfa. Eur. J. Cancer, 2005.
May:
41(8): 1140-9.
- Cortesi, E. Gascon, P., Henry,
D. et al. Standard of care for cancer-related
anemia: improving
hemoglobin levels and quality of life.
Oncology, 2005: 68 Suppl 1: 22-32.
- Henry, DH.
Epoetin alfa for the treatment of cancer
and chemotherapy-related anemia: product
review and update. Expert Opin Pharmacother.
2005 Feb; 6(2); 295-310.
- Lalezari, JP, Bellos,
NC, Santhasivam, K., Richmond, GJ, Cohen, CJ,
Myers, RA, Henry, DH. T-
1249 retains potent antiretroviral activity
in patients who had experienced virological
failure while
on an enfuvirtide-containing treatment regimen.
J. Infect. Disease 2005, Apr. 1:191(7): 1155-63.
- Henry,
DH, Lucio, N.G., Charu, V., et al. Randomized,
open-label comparison of epoetin alfa extended
dosing (80,000 U Q2W) vs. weekly dosing (40,000
U QW) in patients with chemotherapy-induced
anemia. Current Medical Research and Opinion,
22(7) 2006, 1403-1413.
Arthur
Staddon, MD, Medical Director of the
Cancer Center,
published the following article:
Staddon, AP, Kilcoyne, S, Latham, JN, Henry,
DH. Tolerability of pegylated liposomal doxorubicin
20 mg/m2 every 2 weeks in the management of solid
or hematologic malignancies. Proc ASCO
18S: 18500; 2006.
|
